<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"><channel><title><![CDATA[THERAVECTYS 보도자료 - 뉴스와이어]]></title><link>https://www.newswire.co.kr/?md=A10&amp;act=article&amp;no=24546></link><description><![CDATA[THERAVECTYS 보도자료 - 뉴스와이어 RSS 서비스]]></description><lastBuildDate>Sun, 17 May 2026 13:00:13 +0900</lastBuildDate><copyright>Copyright (c) 2004~2026 Korea Newswire All rights reserved</copyright><language>ko-KR</language><item><title><![CDATA[THERAVECTYS Granted Authorization by the French National Agency for Medicines to Produce Lentiviral Vectors for Clinical Use and CAR-T Cell Therapies under GMP Standards]]></title><link>https://www.newswire.co.kr/newsRead.php?no=786744</link><description><![CDATA[PARIS--(Business Wire/Korea Newswire)--THERAVECTYS , a clinical development biotechnology company focusing on the development of therapeutic vaccines and immunotherapies, proudly announces that its manufacturing plant has been granted the status of a GMP pharmaceutical manufacturing establishment, by the French National Agency for Medicines and Health Products Safety (ANSM). The new ...]]></description><pubDate>Tue, 24 Mar 2015 13:20:00 +0900</pubDate></item><item><title><![CDATA[테라벡티스, 프랑스 정부기관서 CAR T-세포 치료제용 렌티바이러스 운반체 생산 위한 GMP 시설기준 인증 획득]]></title><link>https://www.newswire.co.kr/newsRead.php?no=786745</link><description><![CDATA[파리--(Business Wire/뉴스와이어)--치료 백신과 면역 치료제를 전문으로 임상 개발하는 생명공학업체인 테라벡티스(THERAVECTYS, )가 프랑스 국립의약품 및 건강제품안전청(National Agency for Medicines and Health Products Safety, ANSM)으로 부터 자사 제조시설에 대한 GMP(우수제조관리기준)제약시설 인증을 획득했다고 발표했다. 이 신규 시설에서는 1상~3상 임상시험 용 렌티바이러스 운반체(lentivir...]]></description><image><url><![CDATA[https://file.newswire.co.kr/data/datafile2/thumb/2015/03/20150324120741_3039345317.jpg]]></url></image><pubDate>Tue, 24 Mar 2015 13:20:00 +0900</pubDate></item></channel></rss>